

17th MONTREUX *faxBACK* SYMPOSIUM

Please photocopy and fax back to:
Micromass' International Marketing Response Centre

USA: (978) 524 8210

EUROPE: +31 (0) 294 419052

UK / International: +44 (0) 161 282 4400



DEVELOPMENT OF A RAPID AND SENSITIVE METHOD FOR THE QUANTITATION OF AMPHETAMINES IN HUMAN PLASMA

¹Michelle Wood*, ¹Michael Morris, ¹Don Cooper, ²Jan Claereboudt, ³Nele Samyn and ³Gert De Boeck

¹Micromass UK Ltd., Floats Rd, Manchester M23 9LZ, UK.

²Micromass, Mechelsesteenweg 277 Box 9, B-1800 Vilvoorde, Belgium.

³National Institute for Forensic Science (NICC), Belgium.

Please send me information on the following products from Waters and Micromass:

- | |
|---------------------------------------------------------------|
| <input type="checkbox"/> Micromass' TofSpec 2E™ |
| <input type="checkbox"/> Micromass' GCT™ |
| <input type="checkbox"/> Micromass' AutoSpec™ NT |
| <input type="checkbox"/> Micromass' OpenLynx™ |
| <input type="checkbox"/> Micromass' QuanLynx™ |
| <input type="checkbox"/> Micromass' MetaboLynx™ |
| <input type="checkbox"/> Micromass' ProteinLynx™ |
| <input type="checkbox"/> Micromass' MassPrep Station™ |
| <input type="checkbox"/> Micromass' M@LDI™ |
| <input type="checkbox"/> Micromass' MicrobeLynx™ |
| <input type="checkbox"/> Micromass' ProteomeWorks™ System |
| <input type="checkbox"/> Micromass' Platform ICP™ <i>Life</i> |

☒ please tick relevant box(s)

- | |
|------------------------------------------------------------|
| <input type="checkbox"/> Waters' CapLC™ System |
| <input type="checkbox"/> Waters' Alliance® HT System |
| <input type="checkbox"/> Micromass' LCT™ |
| <input type="checkbox"/> Micromass' MUX-technology™ |
| <input type="checkbox"/> Micromass' LockSpray™ |
| <input type="checkbox"/> Micromass' Quattro LC™ |
| <input type="checkbox"/> Micromass' Quattro Ultima™ |
| <input type="checkbox"/> Micromass' Q-ToF™ 2 |

Name: _____
Position: _____
Organization: _____
Address: _____

Tel: _____ Fax: _____ e-mail: _____
Application: _____

I intend to evaluate/purchase the following MS technologies:

- ☐ Immediately ☐ Within 3-9 months ☐ Not planned

MICROMASS UK Limited
Floats Road
Wythenshawe
Manchester M23 9LZ
Tel: +44 (0) 161 945 4170
Fax: +44 (0) 161 998 8915
<http://www.micromass.co.uk>

UK Sales Desk Tel: 0161 946 0565
USA Beverly MA, Tel: 978 524-8200
Canada Pte-Claire, Tel: 514 694-1200
EUROPE Weesp, Tel: +31 (0) 294-480484
Austria Neudorf, Tel: 223 6892 444
Belgium Vilvoorde, Tel: 02-2534550
France Villeurbanne, Tel: 04 72 14 89 00
Germany Eschborn, Tel: 0800-1817249
Italy Milan, Tel: 02 2159 1415
Netherlands Weesp, Tel: 0294-480484
Spain Barcelona, Tel: 932 466696
Switzerland Sissach, Tel: 061-9730800
NORDIC Täby, Tel: +46 (0) 8 555 115 10
Denmark Hedehusene, Tel: 4657 4101
Sweden Täby, Tel: 08 555 115 10



Certificate No: 951387

Poster No. MMP/122/LAG/V1/00

The product information in this document was correct at the time of printing, however specifications are subject to alteration without notice. Information contained herein should not be construed as a contractual commitment either by Bio-Rad Laboratories, Micromass Limited or Waters Corporation. All orders are accepted subject to Micromass' current Conditions of Sale.

For research use only.

Not for use in diagnostic procedure.

Microsoft Windows NT is a registered trademark of the Microsoft Corporation. No attempt is made to supersede this or any other copyrights.

© Micromass Limited, November 2000

Micromass is a division of Waters Corporation

GC-MS

LC-MS

LC-MS-MS

MALDI-MS

ICP-MS

LC-ICP-MS

IR-MS



Presented at:

17th MONTREUX SYMPOSIUM

SWITZERLAND

8 - 10th November, 2000

*To whom all correspondence should be addressed:

Tel: + 44 (0) 161 945 4170

Fax: + 44 (0) 161 998 8915

e-mail: michelle.wood@micromass.co.uk

For more information please contact your local Micromass office or visit our web site: www.micromass.co.uk

Outline

To develop a rapid sensitive LC-MS/MS method for the simultaneous quantitation of amphetamines in plasma. The method should require minimal sample preparation.

Introduction

- 'Ecstasy' (MDMA), 'EVE' (MDEA) and MDA are amongst the most frequently used recreational drugs.
- Acute toxicity problems include hyperthermia, convulsions and arrhythmias. In addition, there are growing concerns of the long-term effects particularly regarding neurotoxicity.
- Target analysis of these drugs and other amphetamines in biological samples is of great importance for clinical and forensic toxicologists alike. The challenge is to analyse such compounds and their metabolites in a limited volume physiological sample.
- At present, most laboratories use GC-MS for this purpose. However, this procedure is very labour-intensive and time-consuming, particularly as solid-phase extraction and derivatization is unavoidable.
- Here we describe the development of an alternative method. Amphetamines were isolated from plasma using a simple methanol extraction procedure and subsequently analysed using HPLC-MS-MS. The developed method has a total analysis time (including sample preparation) of less than 15 minutes and allows the simultaneous analysis of several amphetamines in plasma. Limits of detection of 1ng/ml plasma (or better) were achieved.

Experimental Conditions

LC conditions

HPLC System: Waters Alliance 2690
Column: Hypersil BDS C₁₈ (100mm x 2.1mm, 3.5µm)
Mobile phase: (A) = 10mM ammonium acetate
(B) = 95% acetonitrile :5% 10mM ammonium acetate
Isocratic elution (85:15)

Flow rate: 0.3mL/min
Injection volume: 10µL

MS conditions

Mass spectrometer: Micromass Quattro Ultima (Figure 1)
Ionisation mode: ES positive ion
Capillary voltage: 3kV
MS/MS: Collision gas: Argon at 2.5 x 10⁻³ mbar

The Quattro Ultima triple quadrupole mass spectrometer incorporating 'Z' Spray source



Figure 1

Results and Discussion

Figure 2 shows the resulting MS and MS-MS spectra for 'Ecstasy' (MDMA), 'Eve' (MDEA), MDA, Amphetamine, Methamphetamine and Ephedrine.




Figure 2

Isotopically labelled internal standards (Radian International) were used for quantification. Table 1 summarises the multiple reaction monitoring (MRM) transitions and conditions used in the analysis of the amphetamines and their deuterated analogues.

Compound	Precursor (m/z)	Product (m/z)	Cone Voltage (V)	Collision energy (eV)
MDEA	208	163	50	12
MDEA D5	213	163	50	12
Methamphetamine	150	91	50	15
Methamphetamine D14	164	98	50	18
Amphetamine	136	91	60	17
Amphetamine D11	147	98	60	16
Ephedrine	166	148	30	12
Ephedrine D3	169	151	40	12
MDA	180	163	30	8
MDA D5	185	168	50	10
MDMA	194	163	60	12
MDMA D5	199	165	60	13

Table 1 MRM transitions and conditions for the measurement of several amphetamines and their internal standards

Figure 3 shows the MRM chromatograms acquired simultaneously during a single injection (6 out of 12 shown). The typical linearity of response (over 4 orders of magnitude) is demonstrated in Figures 4a and 4b.




Figure 3

Typical linearity of response, obtained over 4 orders of magnitude, for MDMA (diluted in mobile phase)




Figure 4a

Typical linearity of response, obtained over 4 orders of magnitude, for MDEA (diluted in mobile phase)




Figure 4b

The experiment was extended to include the determination in 'real' biological matrices by isolating the amphetamines from plasma (methanol extraction) prior to analysis using HPLC/MS/MS. This simple isolation step takes a fraction of the time needed to prepare samples for typical GC-MS analysis (see Figure 5). Once again responses were linear over the four orders of magnitude investigated (Coefficient of Determination > 0.99). Spiked 'Test' plasmas were successfully identified and quantified using the developed method (see Figure 6).

Method comparison chart




Figure 5

HPLC/MS/MS analysis of 'Test plasma 1' and 'Test plasma 2'. Samples were correctly identified and quantified as MDA and MDMA respectively




Figure 6

In an aim to further increase the sensitivity of analysis of this group of amphetamines, the potential use of a simple concentration step was investigated. Methanol extracts were dried using a GyroVap™ vacuum concentrator and then reconstituted in 100µL mobile phase prior to HPLC/MS/MS analysis. The amphetamines were quantified in reference to their respective internal standards. The results (Figure 7) demonstrate that the use of internal standards provides a highly successful method of quantifying the amphetamines in extracted plasma and offers increased 'real' sample throughput by negating the need for full standard curves. In addition, the vacuum concentration step is a successful technique by which the sensitivity of analysis may be increased.

Typical linearity of response for plasmas containing MDEA and Ephedrine. Amphetamine spiked plasma was firstly extracted using methanol. Following centrifugation, supernatants were dried using a vacuum concentrator before reconstitution in mobile phase and HPLC/MS/MS analysis. Amphetamines were quantified by reference to their internal standards




Figure 7

Conclusion

We have developed a simple, rapid method which allows the simultaneous quantitation of several amphetamines in plasma during a single chromatographic run. The procedure which involves the extraction of amphetamines from plasma followed by HPLC/MS/MS analysis is less time consuming and labour-intensive than the existing method. It has been successfully applied to 'Test' plasma samples.

Future aims

- To extend these investigations in order to fully validate the method against the current GC/MS methodology.
- To apply the validated method to other biological fluids such as saliva and urine.